BTG

(redirected from BTG plc)
Also found in: Dictionary, Wikipedia.

BTG

A British pharmaceutical company. It develops drugs for cancer, neurological disorders and other diseases and sells them to hospitals and others. It traces its origins to the 1940s and was founded in its current form in 1991 as the British Technology Group. It is publicly traded and is included on the FTSE 250.

BTG

see BRITISH TECHNOLOGY GROUP.
References in periodicals archive ?
On June 11, 2014, EKOS Corporation, a company of BTG Group (that comprises of BTG plc and other companies), announced the initiation of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS System (ACCESS PTS) Study.
Primaxis, founded in 1998 by RBC Technology Ventures and BTG PLC, was created to increase the availability of seed capital in the Canadian marketplace.
BTG plc is a London Stock Exchange techMARK listed company, which is quoted under the symbol "BGC.
30 /PRNewswire/ -- Asterand plc (London Stock Exchange: ATD) announced that it has entered into an exclusive license agreement with BTG plc , the UK based medical innovations company whereby BTG acquires the rights to a series of compounds discovered and developed by Asterand to treat painful conditions such as migraine headache.
BTG plc (LSE: BGC), the global technology commercialization company, today announced a collaboration with Semiconductor Insights (SI), the leader in technical and patent analyses of integrated circuits and structures, to help semiconductor intellectual property (IP) owners maximize the return on their investments.
Previous investors Bay City Capital, BTG plc, Frazier Healthcare Ventures, InterWest Partners, St.
BTG plc (LSE: BGC), the global technology commercialization company, will hold its Annual General Meeting today at 10.
CONTACT: Andrew Burrows of BTG plc, +011-44-207-575-1741; or Jim Prout of Taylor Rafferty, +1-212-889-4350, for BTG plc
BTG plc (LSE: BGC), the global technology commercialization company, today announced the preliminary results of a pivotal European Phase III trial of the VARISOLVE(R) endovenous microfoam procedure, being developed by its subsidiary Provensis Ltd.
discretionary clients (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to Biocompatibles International plc whose relevant securities this form relates: Use a separate form for each offeror/ offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 22 November 2010 (f) Has the discloser previously disclosed, Yes - BTG plc or are they today disclosing, under the Code in respect of any other party to this offer?
Contact: Andy Burrows BTG plc Director of Investor Relations +44 (0)20 7575 1741 - or - Christine Soden Chief Financial Officer +44 (0)20 7575 1591 - or - Jim Prout Taylor Rafferty 1-212-889-4350
relates: Use a separate form for each offeror/ offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 08 December 2010 (f) Has the discloser previously disclosed, Yes - BTG plc or are they today disclosing, under the Code in respect of any other party to this offer?